July 12, 2023 06:09 AM EDTUpdated 07:29 AM
Deals
Law

EU or­ders Il­lu­mi­na to pay $476M fine over un­ap­proved Grail deal

Jared Whitlock

Features Editor

Il­lu­mi­na must pay a €432 mil­lion ($476 mil­lion) fine for buy­ing the can­cer-test­ing firm Grail with­out reg­u­la­to­ry ap­proval, the Eu­ro­pean Com­mis­sion said to­day.

The San …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times